Opportunity Information: Apply for RFA CA 20 027
This funding opportunity, RFA-CA-20-027, is a National Cancer Institute (NCI) R01 grant announcement designed to support research that reduces illness (morbidity) and improves care and health-related quality of life for people who survived cancer diagnosed in childhood, adolescence, or as adolescents and young adults (AYA). The focus is on the long-term needs of survivors, recognizing that many face ongoing medical, psychological, and social challenges after treatment ends, including late effects of therapy, risk of recurrence, and risk of subsequent (second) cancers. The announcement allows a broad range of study types, including mechanistic work that helps explain how and why health problems develop after treatment, observational studies that track outcomes and identify patterns or predictors, and intervention studies that test strategies to improve care and reduce long-term burden. Clinical trials are optional, meaning applicants can propose trials if appropriate, but they are not required.
NCI highlights six major research domains to guide applications. First, the FOA prioritizes research on disparities in survivor outcomes, including differences tied to race, ethnicity, geography, income, insurance status, and other structural or social factors that influence long-term health. Second, it seeks studies on barriers to appropriate follow-up care, such as problems with access to survivorship services, gaps in continuity of care when patients age out of pediatric systems, limited specialist availability, costs, transportation, health literacy, and challenges with adherence to surveillance and preventive recommendations. Third, it encourages work that examines how family context, socioeconomic circumstances, and broader environmental conditions shape survivor outcomes, including the ways caregiver support, household stressors, neighborhood resources, education, employment, and social determinants of health influence recovery and long-term wellbeing.
Fourth, the FOA calls for research that improves how clinicians identify which survivors need what kind of long-term follow-up, and when. That includes developing or validating indicators, markers, or risk stratification approaches that can guide survivorship care based on an individual’s treatment exposures and evolving health risks for late effects, recurrence, and subsequent cancers. Fifth, the announcement supports studies that clarify risk factors and predictors of late and long-term effects from cancer treatment, which can include cardiotoxicity, endocrine and fertility problems, neurocognitive impacts, psychosocial outcomes, chronic pain and fatigue, secondary malignancies, and other organ-specific or functional complications. Sixth, it invites development and testing of targeted interventions aimed at directly reducing burden for pediatric and AYA survivors. These interventions could be clinical, behavioral, psychosocial, care-delivery, or technology-enabled, as long as they are designed to measurably improve survivorship outcomes, reduce morbidity, or improve quality of life.
The grant mechanism is an NIH R01, which generally supports investigator-initiated, multi-year research projects and can accommodate diverse designs, from cohort studies and secondary data analyses to clinic-based or community-based interventions. The activity category is listed under education and health, and the associated CFDA numbers are 93.393, 93.394, and 93.399, reflecting NCI’s broader cancer research assistance programs. While the source listing does not specify an award ceiling or number of expected awards, the intent is to fund high-impact projects that can move survivorship care forward in a practical way, either by explaining mechanisms, identifying actionable risk factors, improving follow-up systems, or producing scalable interventions.
Eligibility is intentionally broad to encourage participation from many types of institutions and communities that serve survivors. Eligible applicants include state, county, and local governments; public and private institutions of higher education; independent school districts; special district governments; federally recognized Native American tribal governments and other tribal organizations; public housing authorities/Indian housing authorities; nonprofits (with or without 501(c)(3) status); for-profit organizations (other than small businesses) as well as small businesses; and other organizations. The FOA also explicitly notes additional eligible applicant categories such as Historically Black Colleges and Universities (HBCUs), Hispanic-serving Institutions, Tribally Controlled Colleges and Universities (TCCUs), Alaska Native and Native Hawaiian Serving Institutions, Asian American Native American Pacific Islander Serving Institutions (AANAPISIs), faith-based or community-based organizations, regional organizations, eligible federal agencies, U.S. territories or possessions, and non-U.S. entities (foreign organizations). This wide eligibility aligns with the FOA’s emphasis on disparities, access, and real-world survivorship care challenges across different settings.
Administrative details from the source information include the agency (National Institutes of Health, with NCI as the sponsoring institute), the opportunity category (discretionary), and the original closing date listed as 2021-07-30, with a creation date of 2020-03-16. In practical terms, the opportunity is aimed at generating evidence that helps pediatric and AYA cancer survivors live healthier lives long after treatment, by improving how survivorship risks are predicted, how follow-up care is delivered and accessed, and how interventions are tailored to reduce long-term complications and inequities in outcomes.Apply for RFA CA 20 027
- The National Institutes of Health in the education, health sector is offering a public funding opportunity titled "Research to Reduce Morbidity and Improve Care for Pediatric, and Adolescent and Young Adult (AYA) Cancer Survivors (R01 Clinical Trial Optional)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.393, 93.394, 93.399.
- This funding opportunity was created on 2020-03-16.
- Applicants must submit their applications by 2021-07-30. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Eligible applicants include: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public and State controlled institutions of higher education, Native American tribal governments (Federally recognized), Public housing authorities/Indian housing authorities, Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education, Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education, Private institutions of higher education, For-profit organizations other than small businesses, Small businesses, Others.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Frequently Asked Questions (FAQs) - RFA-CA-20-027 (NCI R01) Pediatric and AYA Cancer Survivorship Research
What is RFA-CA-20-027?
RFA-CA-20-027 is a National Cancer Institute (NCI) funding opportunity announcement for an NIH R01 research grant focused on improving long-term outcomes for people who survived cancer diagnosed in childhood, adolescence, or as adolescents and young adults (AYA).
What is the main purpose of this funding opportunity?
The purpose is to support research that reduces illness (morbidity), improves care, and improves health-related quality of life for pediatric and AYA cancer survivors, especially in the years after treatment ends when late effects and other long-term challenges can emerge.
Who is the target population for the research?
The target population is survivors of cancers diagnosed during childhood, adolescence, or during the adolescent and young adult (AYA) period.
Why is survivorship research emphasized in this announcement?
The announcement emphasizes survivorship because many pediatric and AYA survivors experience ongoing medical, psychological, and social challenges after treatment, including late effects of therapy, risk of recurrence, and risk of subsequent (second) cancers.
What types of studies are allowed under this FOA?
A broad range of study types are allowed, including mechanistic studies (to understand how and why post-treatment health problems develop), observational studies (to track outcomes and identify patterns or predictors), and intervention studies (to test strategies that improve care and reduce long-term burden).
Are clinical trials required?
No. Clinical trials are optional under this funding opportunity. Applicants may propose a clinical trial if it fits the research goals, but a trial is not required.
What are the major research domains highlighted by NCI?
NCI highlights six major research domains: (1) disparities in survivor outcomes; (2) barriers to appropriate follow-up care; (3) family, socioeconomic, and environmental influences on outcomes; (4) improving identification of which survivors need what follow-up and when (risk stratification/markers); (5) risk factors and predictors of late and long-term effects; and (6) development and testing of targeted interventions to reduce burden and improve survivorship outcomes.
What does the FOA mean by disparities in survivor outcomes?
Disparities refer to differences in survivorship outcomes linked to factors such as race, ethnicity, geography, income, insurance status, and other structural or social conditions that influence long-term health and access to quality survivorship care.
What kinds of follow-up care barriers are in scope?
In-scope barriers include access challenges to survivorship services, disruptions in continuity of care when survivors age out of pediatric systems, limited specialist availability, costs, transportation issues, health literacy challenges, and difficulties adhering to surveillance and preventive care recommendations.
How does the FOA treat family context and social determinants of health?
The FOA encourages research on how family support, caregiver circumstances, household stressors, neighborhood resources, education, employment, and other socioeconomic and environmental conditions shape long-term outcomes and wellbeing for survivors.
What does "risk stratification" mean in this context?
Risk stratification refers to approaches that help clinicians determine which survivors need specific types of long-term follow-up care, and when, based on factors such as treatment exposures and evolving risks for late effects, recurrence, and subsequent cancers.
What kinds of markers or indicators might be relevant to survivorship follow-up?
The FOA broadly references development or validation of indicators, markers, or other approaches that can guide survivorship care tailored to an individual survivor's treatment history and long-term risk profile.
What late and long-term effects are mentioned as research topics?
Examples include cardiotoxicity, endocrine problems, fertility issues, neurocognitive impacts, psychosocial outcomes, chronic pain, fatigue, secondary malignancies, and other organ-specific or functional complications.
What types of interventions are encouraged?
The FOA invites targeted interventions that are clinical, behavioral, psychosocial, care-delivery focused, or technology-enabled, as long as they are designed to measurably improve survivorship outcomes, reduce morbidity, or improve quality of life for pediatric and AYA survivors.
Can projects focus on improving survivorship care delivery rather than testing a new drug or therapy?
Yes. The FOA explicitly supports studies aimed at improving follow-up systems and care delivery, including identifying and addressing real-world gaps that affect survivor health and access to appropriate long-term care.
What grant mechanism supports this opportunity?
This opportunity uses the NIH R01 mechanism, which typically supports investigator-initiated, multi-year research projects and can accommodate a wide range of research designs.
What kinds of project designs can an R01 support under this FOA?
The FOA notes that R01 projects can include diverse designs such as cohort studies, secondary data analyses, clinic-based interventions, and community-based interventions, among other approaches aligned with the survivorship research goals.
Which agency and institute sponsor the funding opportunity?
The funding opportunity is under the National Institutes of Health (NIH), sponsored by the National Cancer Institute (NCI).
What is the opportunity category?
The opportunity category is listed as discretionary.
What activity category is associated with this opportunity?
The activity category is listed under education and health.
What CFDA numbers are associated with this FOA?
The associated CFDA numbers are 93.393, 93.394, and 93.399, which align with NCI cancer research assistance programs.
Is there an award ceiling or a stated number of awards?
The provided source information does not specify an award ceiling or the number of expected awards.
What types of applicants are eligible to apply?
Eligibility is broad. Eligible applicants include state, county, and local governments; public and private institutions of higher education; independent school districts; special district governments; federally recognized Native American tribal governments and other tribal organizations; public housing authorities/Indian housing authorities; nonprofits (with or without 501(c)(3) status); for-profit organizations (other than small businesses) as well as small businesses; and other organizations.
Are minority-serving institutions and community-based organizations eligible?
Yes. The FOA explicitly includes eligibility for organizations such as HBCUs, Hispanic-serving Institutions, Tribally Controlled Colleges and Universities (TCCUs), Alaska Native and Native Hawaiian Serving Institutions, Asian American Native American Pacific Islander Serving Institutions (AANAPISIs), and faith-based or community-based organizations.
Can non-U.S. (foreign) organizations apply?
Yes. The FOA explicitly lists non-U.S. entities (foreign organizations) as eligible applicants.
Are U.S. territories or possessions included in eligible applicant categories?
Yes. U.S. territories or possessions are explicitly listed among the eligible applicant categories.
Can federal agencies apply?
Yes. Eligible federal agencies are included in the list of eligible applicants.
What is the original closing date listed for this opportunity?
The original closing date listed in the source information is 2021-07-30.
When was this opportunity created?
The creation date listed in the source information is 2020-03-16.
What kinds of outcomes or impact is NCI looking for?
The FOA emphasizes high-impact projects that can move survivorship care forward in practical ways, such as explaining mechanisms behind late effects, identifying actionable risk factors, improving follow-up care systems, or producing interventions that are scalable and reduce long-term complications and inequities.
Is research on recurrence risk and second cancers relevant to this FOA?
Yes. The announcement recognizes ongoing risks faced by survivors, including risk of recurrence and risk of subsequent (second) cancers, and supports research that improves long-term monitoring and outcomes related to these risks.
Can an application focus on predictors and patterns of survivorship outcomes over time?
Yes. Observational research that tracks outcomes and identifies patterns or predictors is explicitly within scope.
Does the FOA support research that explains how late effects develop after treatment?
Yes. Mechanistic work that helps explain how and why health problems develop after treatment is specifically included among the allowable study types.
Does the FOA prioritize real-world access and continuity-of-care problems?
Yes. Barriers to appropriate follow-up care and continuity issues (including transitions when survivors age out of pediatric systems) are a highlighted research domain.
Browse more opportunities from the same category: Education, Health
Next opportunity: Addressing Racial Disparities in Maternal Mortality and Morbidity (R01 Clinical Trial Optional)
Previous opportunity: FY 2020 AmeriCorps Tribes Grants
Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for RFA CA 20 027
Applicants also applied for:
Applicants who have applied for this opportunity (RFA CA 20 027) also looked into and applied for these:
| Funding Opportunity |
|---|
| Research to Reduce Morbidity and Improve Care for Pediatric, and Adolescent and Young Adult (AYA) Cancer Survivors (R21 Clinical Trial Optional) Apply for RFA CA 20 028 Funding Number: RFA CA 20 028 Agency: National Institutes of Health Category: Education, Health Funding Amount: $200,000 |
| NIDA Small Research Grant Program (R03 Clinical Trial Required) Apply for PA 20 146 Funding Number: PA 20 146 Agency: National Institutes of Health Category: Education, Health Funding Amount: $50,000 |
| Extracellular RNA carrier subclasses in processes relevant to Substance Use Disorders or HIV infection (R21- Clinical Trial Not Allowed) Apply for PAR 20 148 Funding Number: PAR 20 148 Agency: National Institutes of Health Category: Education, Health Funding Amount: $200,000 |
| Exploiting in vivo or in situ imaging approaches to understand HIV-relevant processes in the context of substance use disorders (R61/R33 Clinical Trials Optional) Apply for RFA DA 21 005 Funding Number: RFA DA 21 005 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Extracellular RNA carrier subclasses in processes relevant to Substance Use Disorders or HIV infection (R01- Clinical Trial Not Allowed) Apply for PAR 20 147 Funding Number: PAR 20 147 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Academic-Industrial Partnerships (AIP) to Translate and Validate In Vivo Imaging Systems (R01 Clinical Trial Optional) Apply for PAR 20 155 Funding Number: PAR 20 155 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Mechanisms and Consequences of Sleep Disparities in the U.S. (R01 - Clinical Trial Not Allowed) Apply for PAR 20 164 Funding Number: PAR 20 164 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Addressing Racial Disparities in Maternal Mortality and Morbidity (R01 Clinical Trial Optional) Apply for RFA MD 20 008 Funding Number: RFA MD 20 008 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Reducing Stigma Related to Drug Use in Human Service Settings (R34 Clinical Trial Required) Apply for RFA DA 21 001 Funding Number: RFA DA 21 001 Agency: National Institutes of Health Category: Education, Health Funding Amount: $225,000 |
| Reducing Stigma Related to Drug Use in Human Service Settings (R21 Clinical Trial Optional) Apply for RFA DA 21 002 Funding Number: RFA DA 21 002 Agency: National Institutes of Health Category: Education, Health Funding Amount: $200,000 |
| New Informatics Tools and Methods to Enhance U.S. Cancer Surveillance Research (U01 Clinical Trial Optional) Apply for PAR 20 170 Funding Number: PAR 20 170 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Long-Term Effects of Disasters on Health Care Systems Serving Health Disparity Populations (R01- Clinical Trial Optional) Apply for PA 20 172 Funding Number: PA 20 172 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Identifying Innovative Mechanisms or Interventions that Target Multimorbidity and Its Consequences (R01 Clinical Trial Optional) Apply for PAR 20 180 Funding Number: PAR 20 180 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Advancing Research to Develop Improved Measures and Methods for Understanding Multimorbidity (R01 Clinical Trial Optional) Apply for PAR 20 179 Funding Number: PAR 20 179 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Research Project Grant (Parent R01 Clinical Trial Required) Apply for PA 20 183 Funding Number: PA 20 183 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Large scale mapping and/or molecular profiling of ensembles and/or cell-types mediating opioid action in the rodent brain (R01 - Clinical Trial Not Allowed) Apply for PAR 20 182 Funding Number: PAR 20 182 Agency: National Institutes of Health Category: Education, Health Funding Amount: $1,000,000 |
| Mentored Research Scientist Development Award (Parent K01 - Independent Clinical Trial Not Allowed) Apply for PA 20 190 Funding Number: PA 20 190 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Substance Use/Substance Use Disorder Dissertation Research Award (R36 - Clinical Trials Optional) Apply for PA 20 208 Funding Number: PA 20 208 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Single Cell Opioid Responses in the Context of HIV (SCORCH) Program Expansion: CNS Data Generation for Chronic Opioid, Methamphetamine, and/or Cocaine Exposures (U01 Clinical Trial Not Allowed) Apply for RFA DA 21 019 Funding Number: RFA DA 21 019 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| HIV Infection of the Central Nervous System (R01 Clinical Trial Not Allowed) Apply for PA 20 149 Funding Number: PA 20 149 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Inside Our Applicants Portal
Access Applicants Portal
- Grants Repository - Access current and historic funding opportunities with ease. Thousands of funding opportunities are published every week. We can help you sort through the database and find the eligible ones to apply for.
- Applicant Video Guides - The grant application process can be challenging to follow. We can help you with intuitive video guides to speed up the process and eliminate errors in submissions.
- Grant Proposal Wizard - We have developed a network of private funding organizations and investors across the United States. We can reach out and submit your proposal to these contacts to maximize your chances of getting the funding you need.
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Learn More
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "RFA CA 20 027", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.